This week, six pharmaceutical stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

NuPathe Inc. (PATH) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. NuPathe develops pharmaceutical products used for the treatment and management of neurological and psychiatric diseases. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, PATH also gets A’s. For more information, get Portfolio Grader’s complete analysis of PATH stock.

GW Pharmaceuticals PLC Sponsored ADR (GWPH) earns a B this week, jumping up from last week’s grade of C. For more information, get Portfolio Grader’s complete analysis of GWPH stock.

This week, Watson Pharmaceuticals (WPI) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.

Paratek Pharmaceuticals Inc’s (PRTK) ratings are looking better this week, moving up to an A from last week’s B. For more information, get Portfolio Grader’s complete analysis of PRTK stock.

Cardiome Pharma (CRME) shows solid improvement this week. The company’s rating rises from a C to a B. Cardiome Pharma focuses on the discovery, development, and commercialization of drugs to treat or prevent cardiovascular and other diseases. For more information, get Portfolio Grader’s complete analysis of CRME stock.

This week, AbbVie, Inc.’s (ABBV) ratings are up from a C last week to a B. AbbVie, a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. For more information, get Portfolio Grader’s complete analysis of ABBV stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.